{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,29]],"date-time":"2026-07-29T22:12:26Z","timestamp":1785363146595,"version":"3.55.0"},"reference-count":18,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2013,4,23]],"date-time":"2013-04-23T00:00:00Z","timestamp":1366675200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Int J Clin Oncol"],"published-print":{"date-parts":[[2014,4]]},"DOI":"10.1007\/s10147-013-0562-5","type":"journal-article","created":{"date-parts":[[2013,4,22]],"date-time":"2013-04-22T04:48:35Z","timestamp":1366606115000},"page":"391-396","source":"Crossref","is-referenced-by-count":27,"title":["Association between severe toxicity of nilotinib and UGT1A1 polymorphisms in Japanese patients with chronic myelogenous leukemia"],"prefix":"10.1007","volume":"19","author":[{"given":"Takashi","family":"Shibata","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yosuke","family":"Minami","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ayako","family":"Mitsuma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sachi","family":"Morita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Megumi","family":"Inada-Inoue","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomoyo","family":"Oguri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomoya","family":"Shimokata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mihoko","family":"Sugishita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomoki","family":"Naoe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuichi","family":"Ando","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2013,4,23]]},"reference":[{"key":"562_CR1","doi-asserted-by":"crossref","first-page":"1765","DOI":"10.1038\/sj.bjc.6603170","volume":"94","author":"E Weisberg","year":"2006","unstructured":"Weisberg E, Manlew P, Mestan J et al (2006) AMN107 (nilotinib): a novel and selective inhibitor of BCR-ABL. Br J Cancer 94:1765\u20131769","journal-title":"Br J Cancer"},{"key":"562_CR2","doi-asserted-by":"crossref","first-page":"2251","DOI":"10.1056\/NEJMoa0912614","volume":"362","author":"G Saglio","year":"2010","unstructured":"Saglio G, Kim D, Issaragrisil S et al (2010) Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia. N Engl J Med 362:2251\u20132259","journal-title":"N Engl J Med"},{"key":"562_CR3","doi-asserted-by":"crossref","first-page":"5325","DOI":"10.1158\/1078-0432.CCR-08-0308","volume":"14","author":"M Hazarika","year":"2008","unstructured":"Hazarika M, Jiang X, Liu Q et al (2008) Tasigna for chronic and accelerated phase Philadelphia chromosome-positive chronic myelogenous leukemia resistant to or intolerant of imatinib. Clin Cancer Res 14:5325\u20135331","journal-title":"Clin Cancer Res"},{"key":"562_CR4","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1038\/leu.2011.217","volume":"26","author":"PJ Shami","year":"2012","unstructured":"Shami PJ, Deininger M (2012) Evolving treatment strategies for patients newly diagnosed with chronic myeloid leukemia: the role of second-generation BCR-ABL inhibitors as first-line therapy. Leukemia 26:214\u2013224","journal-title":"Leukemia"},{"key":"562_CR5","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1016\/S1470-2045(11)70201-7","volume":"12","author":"HM Kantarjian","year":"2011","unstructured":"Kantarjian HM, Hochhaus A, Saglio G et al (2011) Nilotinib versus imatinib for the treatment of patients with newly diagnosed chronic phase, Philadelphia chromosome-positive, chronic myeloid leukemia: 24-month minimum follow-up of the phase 3 randomised ENESTnd trial. Lancet Oncol 12:841\u2013851","journal-title":"Lancet Oncol"},{"key":"562_CR6","doi-asserted-by":"crossref","first-page":"4933","DOI":"10.1182\/blood-2009-07-232595","volume":"114","author":"G Rosti","year":"2009","unstructured":"Rosti G, Palandri F, Castagnetti F et al (2009) Nilotinib for the frontline treatment of Ph\u00a0+\u00a0chronic myeloid leukemia. Blood 114:4933\u20134938","journal-title":"Blood"},{"key":"562_CR7","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1007\/s12185-009-0327-0","volume":"89","author":"A Tojo","year":"2009","unstructured":"Tojo A, Usuki K, Urabe A et al (2009) A Phase I\/II study of nilotinib in Japanese patients with imatinib-resistant or -intolerant Ph+CML or relapsed\/refractory Ph+ALL. Int J Hematol 89:679\u2013688","journal-title":"Int J Hematol"},{"key":"562_CR8","doi-asserted-by":"crossref","first-page":"2311","DOI":"10.1038\/sj.leu.2404827","volume":"21","author":"JB Singer","year":"2007","unstructured":"Singer JB, Shou Y, Giles F et al (2007) UGT1A1 promoter polymorphism increases risk of nilotinib-induced hyperbilirubinemia. Leukemia 21:2311\u20132315","journal-title":"Leukemia"},{"key":"562_CR9","doi-asserted-by":"crossref","first-page":"1868","DOI":"10.1111\/j.1349-7006.2011.02030.x","volume":"102","author":"T Satoh","year":"2011","unstructured":"Satoh T, Ura T, Yamada Y et al (2011) Genotype-directed, dose-finding study of irinotecan in cancer patients with UGT1A1*28 and\/or UGT1A1*6 polymorphisms. Cancer Sci 102:1868\u20131873","journal-title":"Cancer Sci"},{"key":"562_CR10","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1097\/FPC.0b013e328014341f","volume":"17","author":"H Minami","year":"2007","unstructured":"Minami H, Sai K, Saeki M et al (2007) Irinotecan pharmacokinetics\/pharmacodynamics and UGT1A genetic polymorphisms in Japanese: roles of UGT1A1*6 and *28. Pharmacogenet Genomics 17:497\u2013504","journal-title":"Pharmacogenet Genomics"},{"key":"562_CR11","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1038\/clpt.2008.152","volume":"85","author":"N Yamamoto","year":"2009","unstructured":"Yamamoto N, Takahashi T, Kunikane H et al (2009) PhaseI\/II pharmacokinetic and pharmacogenomic study of UGT1A1 polymorphism in elderly patients with advanced non-small cell lung cancer treated with irinotecan. Clin Pharmacol Ther 85:149\u2013154","journal-title":"Clin Pharmacol Ther"},{"key":"562_CR12","doi-asserted-by":"crossref","first-page":"1479","DOI":"10.1373\/clinchem.2004.034694","volume":"50","author":"Y Hasegawa","year":"2004","unstructured":"Hasegawa Y, Sarashina T, Ando M et al (2004) Rapid detection of UGT1A1 gene polymorphisms by newly developed Invader assay. Clin Chem 50:1479\u20131480","journal-title":"Clin Chem"},{"key":"562_CR13","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1056\/NEJMra032426","volume":"350","author":"DM Roden","year":"2004","unstructured":"Roden DM (2004) Drug-induced prolongation of the QT interval. N Engl J Med 350:1013\u20131022","journal-title":"N Engl J Med"},{"key":"562_CR14","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.jacc.2005.08.059","volume":"47","author":"R Roberts","year":"2000","unstructured":"Roberts R (2000) Genomics and cardiac arrhythmias. J Am Coll Cardiol 47:9\u201321","journal-title":"J Am Coll Cardiol"},{"key":"562_CR15","first-page":"6921","volume":"60","author":"Y Ando","year":"2000","unstructured":"Ando Y, Saka H, Ando M et al (2000) Polymorphisms of UDP-glucuronosyltransferase gene and irinotecan toxicity: a pharmacogenetic analysis. Cancer Res 60:6921\u20136926","journal-title":"Cancer Res"},{"key":"562_CR16","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1124\/dmd.104.001800","volume":"33","author":"N Kaniwa","year":"2005","unstructured":"Kaniwa N, Kurose K, Jinno H et al (2005) Racial variability in haplotype frequencies of UGT1A1 and glucuronidation activity of a novel single nucleotide polymorphism 686C\u00a0>\u00a0T (P229L) found in an African-American. Drug Metab Dispos 33:458\u2013465","journal-title":"Drug Metab Dispos"},{"key":"562_CR17","first-page":"927","volume":"71","author":"Y Liu","year":"2011","unstructured":"Liu Y, Ramirez J, Ratain MJ (2011) Inhibition of paracetamol glucuronidation by tyrosine kinase inhibitors. Br J Clin Pharmacol 71:927\u2013930","journal-title":"Br J Clin Pharmacol"},{"key":"562_CR18","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1007\/s00280-010-1445-3","volume":"67","author":"K Fujita","year":"2011","unstructured":"Fujita K, Sugiyama M, Akiyama Y et al (2011) The small-molecule tyrosine kinase inhibitor nilotinib is a potent noncompetitive inhibitor of the SN-38 glucuronidation by human UGT1A1. Cancer Chemother Pharmacol 67:237\u2013241","journal-title":"Cancer Chemother Pharmacol"}],"container-title":["International Journal of Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10147-013-0562-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s10147-013-0562-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10147-013-0562-5","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,5,29]],"date-time":"2019-05-29T06:37:31Z","timestamp":1559111851000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s10147-013-0562-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,4,23]]},"references-count":18,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2014,4]]}},"alternative-id":["562"],"URL":"https:\/\/doi.org\/10.1007\/s10147-013-0562-5","relation":{},"ISSN":["1341-9625","1437-7772"],"issn-type":[{"value":"1341-9625","type":"print"},{"value":"1437-7772","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,4,23]]}}}